Welsh Government has approved new advice from the All Wales Medicines Strategy Group (AWMSG) for three medicines.
- Bedaquiline (Sirturo) for the treatment of tuberculosis that affects the lungs when the disease has become resistant to other antibiotics (called multi-drug resistant pulmonary tuberculosis) in adolescents aged from 12 to 17 years who weigh at least 30 kg. It must always be taken together with other medicines for treating tuberculosis.
- Doravirine (Pifeltro) for the treatment of HIV infection in people aged 18 years and older. It must be used in combination with other medicines for HIV. It is not suitable to treat infections caused by HIV that is resistant to doravirine.
- Doravirine/lamivudine/tenofovir disoproxil (Delstrigo) for the treatment of adults infected with HIV-1 without past or present evidence of resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class, lamivudine, or tenofovir.
AWTTC’s Patient Access to Medicines Service (PAMS) supports the AWMSG to assess and monitor new medicines in Wales.